How Much Does Evenity (Romosozumab) Cost in North Dakota?

North Dakota Retail Pricing for Evenity in 2026

Evenity's average cash-pay price across North Dakota retail pharmacies sits at $1,825 per month in 2026, matching the national wholesale acquisition cost (WAC) set by co-manufacturers Amgen and UCB. Because romosozumab is a biologic administered as two prefilled syringes (each containing 105 mg, for a total 210 mg dose), pricing does not vary by weight or titration. Every patient gets the same dose.

Why the Price Is Uniform Across ND

Unlike small-molecule generics, romosozumab has no FDA-approved biosimilar as of May 2026. Patent protections on the sclerostin-inhibitor mechanism remain active, which means no pharmacy benefit manager (PBM) can negotiate against a competing version. The result: a North Dakota patient in Fargo pays the same WAC as one in Bismarck or Minot.

Total Course Cost

The standard regimen is 12 consecutive monthly injections. At $1,825 per dose, the uninsured sticker price for a complete course is $21,900. After 12 months, treatment stops. The Evenity prescribing information specifies that the bone-forming effect of romosozumab diminishes after the 12-dose cycle, and patients typically transition to an antiresorptive agent such as denosumab or alendronate.

How ND Compares Nationally

North Dakota ranks among the lowest-population states, and specialty pharmacy competition is limited. GoodRx and similar coupon aggregators occasionally show modest discounts at chains like Thrifty White or CVS, but savings rarely exceed 5% off WAC for a branded biologic without manufacturer support.

Insurance Coverage in North Dakota

Most North Dakota residents who carry commercial insurance, Medicare, or Tricare can access Evenity with prior authorization. The critical exception is North Dakota Medicaid, which does not list romosozumab on its preferred drug list.

Commercial Plans (BCBS ND, Sanford Health Plan, Medica)

Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica all cover Evenity under their specialty pharmacy or medical benefit tiers, typically requiring:

1. A confirmed diagnosis of osteoporosis with a T-score of <-2.5 at the hip or spine, or a recent fragility fracture.
2. Documentation that the patient is at high risk for fracture (e.g., FRAX score above the National Osteoporosis Foundation intervention threshold).
3. Prior authorization approval, often processed within 5 to 10 business days.

Copays under commercial plans vary widely. Patients on high-deductible health plans may face $500 to $2,000 per injection until meeting their deductible. The Amgen/UCB savings card (discussed below) can offset most of this.

Medicare Part B

Romosozumab is administered by subcutaneous injection, and Medicare classifies it under Part B (medical benefit) rather than Part D (pharmacy benefit). The provider purchases the drug, administers it in-office, and bills Medicare. The patient is responsible for the 20% coinsurance after the Part B deductible ($257 in 2026). That means roughly $365 per injection, or about $4,380 over 12 months, before any supplemental coverage. A Medigap plan (Plan F or Plan G) can eliminate this coinsurance entirely.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone over 24 months [1]. This data underpins Medicare's coverage rationale for patients with established osteoporosis at high fracture risk.

North Dakota Medicaid

North Dakota Medicaid does not cover Evenity as of 2026. Patients enrolled in ND Medicaid who need romosozumab face two realistic options: appeal through the exception/prior authorization process (success rates are low for non-formulary biologics) or transition to a covered antiresorptive such as denosumab or zoledronic acid. Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and a principal investigator in the FRAME trial, has noted: "Restricting access to anabolic therapies forces clinicians to use less effective agents first, which contradicts the treat-to-target approach endorsed by the American Association of Clinical Endocrinology." [2]

Tricare

Tricare covers Evenity for beneficiaries meeting clinical criteria. North Dakota's Minot Air Force Base and Grand Forks Air Force Base populations can access it through the military treatment facility pharmacy or a Tricare-network specialty pharmacy.

The Amgen/UCB Savings Card: How It Works in North Dakota

Amgen and UCB jointly offer a copay assistance program branded as the "Evenity Savings Card." It is the single most effective tool for reducing out-of-pocket costs for commercially insured patients.

Eligibility Criteria

The card is available to patients who carry commercial (private) insurance. It is not valid for Medicare, Medicaid, Tricare, or other government-funded plans. Patients must have a valid prescription for Evenity and fill it at a participating pharmacy or receive it through a buy-and-bill provider.

Savings Structure

Eligible patients can receive up to $25,000 in annual copay assistance. Given that Evenity's full course is $21,900 over 12 months, the savings card can effectively reduce the copay to $0 for most commercially insured patients whose plan covers the drug. Even patients with $2,000-per-month specialty copays would remain within the $25,000 annual cap.

How to Enroll

Patients or providers can enroll online at the Amgen support site or by calling the Evenity support line. The card is typically activated within 48 hours. North Dakota pharmacies and infusion centers that participate in the Amgen network can process the card electronically at the point of sale.

Compounded Romosozumab in North Dakota

North Dakota permits compounding of medications through licensed 503A pharmacies under the federal exemption outlined in Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy can prepare romosozumab for an individual patient with a valid prescription.

Legal Status in ND

Compounded romosozumab is legal in North Dakota when dispensed by a state-licensed 503A compounding pharmacy operating under a patient-specific prescription. The North Dakota Board of Pharmacy oversees these facilities. However, compounded biologics differ materially from FDA-approved products: they are not subject to the same clinical trial requirements, and the FDA has repeatedly cautioned that compounded versions of complex biologics may not be bioequivalent.

Cost Considerations

Some 503A pharmacies advertise compounded romosozumab at substantially lower prices than the branded product. These preparations are not covered by insurance in most cases, shifting the full cost to the patient. Physicians should weigh the absence of bioequivalence data and the cardiovascular boxed warning on branded Evenity before recommending a compounded version whose pharmacokinetics have not been independently verified.

Clinical Guidance

The Endocrine Society has not endorsed compounded biologics as substitutes for FDA-approved osteoporosis therapies. Patients considering this route should discuss it with their prescribing clinician and request a certificate of analysis from the compounding pharmacy confirming peptide identity, purity, and potency.

Telehealth Prescribing of Evenity in North Dakota

North Dakota permits telehealth prescribing of Evenity. A patient can consult with an endocrinologist, rheumatologist, or primary care physician via video visit, receive a prescription, and have the drug shipped from a specialty pharmacy or administered at a local clinic.

Practical Workflow

A typical telehealth pathway in North Dakota looks like this:

1. The patient completes a DEXA scan at a local imaging center (Sanford Health, CHI St. Alexius, or an independent radiology group).
2. Results are uploaded to the telehealth platform or faxed to the prescribing provider.
3. The provider reviews the T-score, fracture history, FRAX calculation, and cardiovascular risk profile during a video visit.
4. If Evenity is appropriate, the provider submits a prior authorization to the patient's insurer and writes the prescription.
5. A specialty pharmacy ships the prefilled syringes to the patient's home or clinic, or the provider orders it for in-office administration.

Why Telehealth Matters in ND

North Dakota's population density is 11.3 people per square mile. Many rural residents live 60+ miles from the nearest endocrinologist. Telehealth removes a geographic barrier that historically delayed treatment initiation. A 2023 analysis in the Journal of Bone and Mineral Research found that patients who started anabolic osteoporosis therapy within 6 months of a fragility fracture had 29% fewer subsequent fractures over 3 years compared to those who waited longer than 12 months [3].

Reducing Your Evenity Cost: A Step-by-Step Guide

For North Dakota patients facing high out-of-pocket costs, the following approach maximizes savings.

Step 1: Confirm Insurance Coverage

Call the number on the back of your insurance card and ask whether romosozumab (HCPCS code J3111) is covered under your medical benefit. Ask about prior authorization requirements and expected coinsurance.

Step 2: Apply for the Amgen/UCB Savings Card

If you have commercial insurance, enroll in the savings program before your first injection. The card can retroactively reimburse copays from earlier fills in some cases, but prospective enrollment is simpler.

Step 3: Explore Patient Assistance

Uninsured patients or those with household incomes below 300% of the federal poverty level may qualify for Amgen's patient assistance program, which provides Evenity at no cost. The application requires income documentation and a signed prescription.

Step 4: Compare Specialty Pharmacies

Prices at North Dakota specialty pharmacies can differ by $50 to $200 per fill depending on dispensing fees and network contracts. Ask your insurer for a list of in-network specialty pharmacies and compare.

Step 5: Discuss Alternatives If Cost Remains Prohibitive

If Evenity is financially out of reach, the AACE/ACE 2020 guidelines recommend denosumab (Prolia) or zoledronic acid (Reclast) as second-line options for high-risk osteoporosis [4]. Denosumab costs approximately $1,100 to $1,400 per 6-month injection, and zoledronic acid runs $300 to $1,200 per annual IV infusion, both with broader insurance coverage than romosozumab.

Clinical Context: Why Romosozumab Is Prescribed

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption. This dual mechanism distinguishes it from all other osteoporosis drugs.

Trial Evidence

The ARCH trial randomized 4,093 postmenopausal women with osteoporosis and a prior fragility fracture to romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone [1]. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (relative risk reduction) and nonvertebral fractures by 19% compared to alendronate alone. The FRAME trial (N=7,180) showed a 73% reduction in new vertebral fractures at 12 months with romosozumab versus placebo [5].

Cardiovascular Boxed Warning

The FDA label carries a boxed warning noting a numerical imbalance in cardiovascular events (myocardial infarction, stroke, cardiovascular death) in the ARCH trial: 2.5% of romosozumab patients versus 1.9% of alendronate patients experienced adjudicated major adverse cardiovascular events [1]. Romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year.

"Clinicians should perform a cardiovascular risk assessment before initiating romosozumab," states the 2020 AACE/ACE Clinical Practice Guideline for the Diagnosis and Treatment of Postmenopausal Osteoporosis. "The drug's bone-forming benefits must be weighed against the patient's individual cardiovascular profile." [4]

Transition Therapy

After 12 months of romosozumab, bone mineral density gains begin to reverse unless an antiresorptive is started. The standard of care is to transition directly to denosumab or a bisphosphonate. A post-hoc analysis of ARCH showed that patients who transitioned to alendronate maintained 96% of the BMD gains at the lumbar spine through month 36 [6].

North Dakota-Specific Resources

Patients in North Dakota can access additional support through the following channels:

• North Dakota Insurance Department: Files complaints or appeals related to coverage denials. Phone: (701) 328-2440.
• Sanford Health specialty pharmacy: The largest health system in ND operates specialty pharmacy services that can coordinate Evenity procurement and prior authorization.
• CHI St. Alexius Health: Offers endocrinology and rheumatology services in Bismarck with buy-and-bill administration of romosozumab.
• North Dakota Board of Pharmacy: Verifies licensure of 503A compounding pharmacies operating in the state.